Xeris Pharmaceuticals Inc (NASDAQ:XERS) Expected to Post Quarterly Sales of $2.17 Million

Equities analysts expect Xeris Pharmaceuticals Inc (NASDAQ:XERS) to report sales of $2.17 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Xeris Pharmaceuticals’ earnings, with estimates ranging from $1.80 million to $2.70 million. Xeris Pharmaceuticals reported sales of $310,000.00 in the same quarter last year, which would suggest a positive year over year growth rate of 600%. The company is expected to issue its next earnings report on Tuesday, August 4th.

On average, analysts expect that Xeris Pharmaceuticals will report full-year sales of $15.01 million for the current fiscal year, with estimates ranging from $12.30 million to $18.10 million. For the next financial year, analysts forecast that the firm will report sales of $59.43 million, with estimates ranging from $54.10 million to $64.40 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Xeris Pharmaceuticals.

Xeris Pharmaceuticals (NASDAQ:XERS) last announced its earnings results on Thursday, May 7th. The company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.03. Xeris Pharmaceuticals had a negative net margin of 3,100.00% and a negative return on equity of 323.82%. The firm had revenue of $1.68 million for the quarter, compared to the consensus estimate of $1.82 million.

Several research analysts have commented on XERS shares. Piper Sandler started coverage on shares of Xeris Pharmaceuticals in a report on Tuesday, February 18th. They set an “overweight” rating and a $12.00 price target for the company. Zacks Investment Research cut shares of Xeris Pharmaceuticals from a “buy” rating to a “hold” rating and set a $4.50 price target for the company. in a report on Saturday, May 16th. Mizuho reiterated a “buy” rating and set a $14.00 price target on shares of Xeris Pharmaceuticals in a report on Tuesday, May 26th. Finally, ValuEngine upgraded shares of Xeris Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Xeris Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $12.13.

NASDAQ XERS traded down $0.34 on Friday, hitting $4.77. 582,700 shares of the stock were exchanged, compared to its average volume of 621,265. The company has a quick ratio of 4.72, a current ratio of 4.82 and a debt-to-equity ratio of 2.16. Xeris Pharmaceuticals has a fifty-two week low of $1.42 and a fifty-two week high of $12.94. The company has a market cap of $192.08 million, a PE ratio of -1.02 and a beta of 2.12. The company has a 50-day moving average price of $3.27 and a 200-day moving average price of $4.91.

In related news, insider John Patrick Shannon, Jr. bought 22,000 shares of the stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average price of $3.55 per share, for a total transaction of $78,100.00. Following the acquisition, the insider now owns 117,493 shares in the company, valued at approximately $417,100.15. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Paul R. Edick bought 33,000 shares of the stock in a transaction dated Friday, May 8th. The stock was bought at an average price of $3.54 per share, with a total value of $116,820.00. Following the acquisition, the insider now owns 95,493 shares in the company, valued at approximately $338,045.22. The disclosure for this purchase can be found here. Corporate insiders own 5.95% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. FMR LLC boosted its stake in Xeris Pharmaceuticals by 29.9% during the 1st quarter. FMR LLC now owns 2,963,018 shares of the company’s stock worth $29,749,000 after purchasing an additional 682,050 shares during the period. ArrowMark Colorado Holdings LLC boosted its stake in Xeris Pharmaceuticals by 21.4% during the 1st quarter. ArrowMark Colorado Holdings LLC now owns 2,341,902 shares of the company’s stock worth $4,567,000 after purchasing an additional 413,594 shares during the period. BlackRock Inc. boosted its stake in Xeris Pharmaceuticals by 6.4% during the 1st quarter. BlackRock Inc. now owns 2,336,418 shares of the company’s stock worth $4,555,000 after purchasing an additional 139,671 shares during the period. Citigroup Inc. boosted its stake in Xeris Pharmaceuticals by 66,662.9% during the 4th quarter. Citigroup Inc. now owns 2,201,839 shares of the company’s stock worth $15,523,000 after purchasing an additional 2,198,541 shares during the period. Finally, State Street Corp boosted its stake in Xeris Pharmaceuticals by 8.3% during the 1st quarter. State Street Corp now owns 542,031 shares of the company’s stock worth $1,057,000 after purchasing an additional 41,630 shares during the period. Hedge funds and other institutional investors own 62.48% of the company’s stock.

Xeris Pharmaceuticals Company Profile

Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.

Recommended Story: What is a Special Dividend?

Get a free copy of the Zacks research report on Xeris Pharmaceuticals (XERS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xeris Pharmaceuticals (NASDAQ:XERS)

Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.